Pfizer Shakes Up R&D Leadership, Streamlining Oncology Ahead Of Seagen Merger

 
• By Jessica Merrill

Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.

Exit door
William Pao is leaving Pfizer's R&D team • Source: Shutterstock

More from Leadership

More from Scrip